Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fredrik Sandin

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
British Journal of Haematology|March 31, 2015
Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor eraNiklas Gunnarsson, Leif Stenke, Martin Höglund, et al.
British Journal of Haematology|March 30, 2021
Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registryHjalmar Flygt, Fredrik Sandin, Torsten Dahlén, et al.
Blood|July 12, 2013
Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registryMartin Höglund, Fredrik Sandin, Karin Hellström, et al.
Blood|June 21, 2011
Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemiaBengt Simonsson, Tobias Gedde-Dahl, Berit Markevärn, et al.
Acta Oncologica (Stockholm, Sweden)|June 21, 2017
U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in SwedenBengt Glimelius, Beatrice Melin, Gunilla Enblad, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
British Journal of Haematology|March 31, 2015
Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor eraNiklas Gunnarsson, Leif Stenke, Martin Höglund, et al.
British Journal of Haematology|March 30, 2021
Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registryHjalmar Flygt, Fredrik Sandin, Torsten Dahlén, et al.
Blood|July 12, 2013
Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registryMartin Höglund, Fredrik Sandin, Karin Hellström, et al.
Blood|June 21, 2011
Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemiaBengt Simonsson, Tobias Gedde-Dahl, Berit Markevärn, et al.
Acta Oncologica (Stockholm, Sweden)|June 21, 2017
U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in SwedenBengt Glimelius, Beatrice Melin, Gunilla Enblad, et al.
Pageof 5